Shattuck Labs to Showcase Innovations at December Investor Events

Introduction to Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a leading biotechnology firm dedicated to developing innovative therapeutics. They focus on addressing unmet medical needs in treating cancer and chronic immune-related diseases.

Participation in Upcoming Investor Conferences

In an exciting move, Shattuck Labs has announced its participation in two significant investor conferences happening this December. As a company at the forefront of biotech research, these conferences provide an excellent platform for Shattuck to connect with investors and share insights into its current projects.

Piper Sandler 36th Annual Healthcare Conference

One of the highlights is the participation in the Piper Sandler 36th Annual Healthcare Conference. Here, Dr. Taylor Schreiber, Shattuck's Chief Executive Officer, will deliver a corporate presentation. This event is scheduled for December 3 and will take place at 12:30 p.m. ET. This is a valuable opportunity for attendees to learn more about the company's strategic direction and innovative therapies.

Evercore 7th Annual HealthCONx Conference

Following that, on December 4, Dr. Schreiber will engage in a fireside chat at the Evercore 7th Annual HealthCONx Conference. This format allows for an informal and engaging discussion around the company’s mission and achievements while providing insights into the fascinating fields of immunology and oncology. The conversation is set for 8:45 a.m. ET, and it promises to touch on pivotal developments in their therapeutic landscape.

Live Webcast Availability

For those unable to attend in person, Shattuck Labs will also provide a live webcast of both events. This webcast will be accessible via the Investors section of their website, ensuring that even those who cannot attend can stay informed about the company’s latest developments. A replay will be made available for up to 90 days post-event, allowing further access to the valuable content shared.

About Shattuck Labs' Research Focus

Shattuck Labs specializes in transformative treatments for autoimmune/inflammatory diseases and cancer through advanced protein engineering. Their lead program, SL-325, represents a groundbreaking approach in targeting TNF superfamily receptors, with the goal of offering first-in-class antibodies aimed at conditions like inflammatory bowel disease (IBD) and other autoimmune disorders.

By utilizing novel TNF receptor agonist and antagonist therapeutics, Shattuck Labs aims to carve out new strategies in the fight against complex diseases. The company's innovative approach highlights its commitment to improving patient outcomes and enhancing the quality of life for those suffering from challenging health conditions.

Company Location and Mission

With operational hubs in Austin, Texas, and Durham, North Carolina, Shattuck Labs is perfectly positioned to foster collaboration and innovation within the biotech ecosystem. Their aim to push the boundaries of treatment possibilities positions them as a vital player in the industry.

Contact Information

For more inquiries regarding investor relations, contact Conor Richardson, the Vice President of Investor Relations at Shattuck Labs, via email at InvestorRelations@shattucklabs.com. Engaging with their investor relations team will provide further insights into Shattuck's future plans and investment opportunities.

Frequently Asked Questions

What is Shattuck Labs known for?

Shattuck Labs is recognized for developing novel therapeutics targeted at cancer and chronic immune-related diseases.

Who will be speaking at the investor conferences?

Dr. Taylor Schreiber, the CEO of Shattuck Labs, will be the presenter at both conferences.

How can I watch the events if I can't attend in person?

The events will be available via live webcast on Shattuck Labs' Investor section of the website.

What is the significance of the SL-325 program?

SL-325 aims to provide a first-in-class treatment for autoimmune diseases, representing a major step forward in therapeutic options.

What is the mission of Shattuck Labs?

Shattuck Labs' mission is to innovate and improve treatment alternatives for patients suffering from complex conditions like cancer and autoimmune diseases.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.